JP6147249B2 - 神経因性疼痛の治療において使用するためのカンナビノイド - Google Patents
神経因性疼痛の治療において使用するためのカンナビノイド Download PDFInfo
- Publication number
- JP6147249B2 JP6147249B2 JP2014510885A JP2014510885A JP6147249B2 JP 6147249 B2 JP6147249 B2 JP 6147249B2 JP 2014510885 A JP2014510885 A JP 2014510885A JP 2014510885 A JP2014510885 A JP 2014510885A JP 6147249 B2 JP6147249 B2 JP 6147249B2
- Authority
- JP
- Japan
- Prior art keywords
- pain
- cannabinoids
- neuropathic pain
- treatment
- cbdv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003557 cannabinoid Substances 0.000 title claims description 69
- 229930003827 cannabinoid Natural products 0.000 title claims description 69
- 229940065144 cannabinoids Drugs 0.000 title claims description 47
- 238000011282 treatment Methods 0.000 title claims description 34
- 208000004296 neuralgia Diseases 0.000 title description 47
- 208000021722 neuropathic pain Diseases 0.000 title description 47
- 208000004454 Hyperalgesia Diseases 0.000 claims description 20
- 206010053552 allodynia Diseases 0.000 claims description 8
- REOZWEGFPHTFEI-JKSUJKDBSA-N Cannabidivarin Chemical compound OC1=CC(CCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 REOZWEGFPHTFEI-JKSUJKDBSA-N 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 241001471082 Colocasia bobone disease-associated cytorhabdovirus Species 0.000 claims 4
- REOZWEGFPHTFEI-UHFFFAOYSA-N cannabidivarine Natural products OC1=CC(CCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 REOZWEGFPHTFEI-UHFFFAOYSA-N 0.000 claims 4
- 208000002193 Pain Diseases 0.000 description 35
- 230000036407 pain Effects 0.000 description 34
- 241001465754 Metazoa Species 0.000 description 24
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 description 20
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 description 20
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 description 20
- 229950011318 cannabidiol Drugs 0.000 description 20
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 description 20
- 230000000694 effects Effects 0.000 description 20
- 241000699670 Mus sp. Species 0.000 description 19
- UVOLYTDXHDXWJU-UHFFFAOYSA-N Cannabichromene Chemical compound C1=CC(C)(CCC=C(C)C)OC2=CC(CCCCC)=CC(O)=C21 UVOLYTDXHDXWJU-UHFFFAOYSA-N 0.000 description 16
- 210000002683 foot Anatomy 0.000 description 13
- UVOLYTDXHDXWJU-NRFANRHFSA-N Cannabichromene Natural products C1=C[C@](C)(CCC=C(C)C)OC2=CC(CCCCC)=CC(O)=C21 UVOLYTDXHDXWJU-NRFANRHFSA-N 0.000 description 12
- ORKZJYDOERTGKY-UHFFFAOYSA-N Dihydrocannabichromen Natural products C1CC(C)(CCC=C(C)C)OC2=CC(CCCCC)=CC(O)=C21 ORKZJYDOERTGKY-UHFFFAOYSA-N 0.000 description 12
- 241000218236 Cannabis Species 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 230000002093 peripheral effect Effects 0.000 description 10
- 238000012360 testing method Methods 0.000 description 9
- 210000005036 nerve Anatomy 0.000 description 8
- 208000027418 Wounds and injury Diseases 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 208000014674 injury Diseases 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 208000028389 Nerve injury Diseases 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 230000008764 nerve damage Effects 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 210000003497 sciatic nerve Anatomy 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 208000001294 Nociceptive Pain Diseases 0.000 description 3
- 239000001961 anticonvulsive agent Substances 0.000 description 3
- 230000003542 behavioural effect Effects 0.000 description 3
- QXACEHWTBCFNSA-SFQUDFHCSA-N cannabigerol Chemical compound CCCCCC1=CC(O)=C(C\C=C(/C)CCC=C(C)C)C(O)=C1 QXACEHWTBCFNSA-SFQUDFHCSA-N 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 230000003040 nociceptive effect Effects 0.000 description 3
- 210000004345 peroneal nerve Anatomy 0.000 description 3
- 239000000419 plant extract Substances 0.000 description 3
- 230000001107 psychogenic effect Effects 0.000 description 3
- 210000001590 sural nerve Anatomy 0.000 description 3
- 210000000689 upper leg Anatomy 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 229940125681 anticonvulsant agent Drugs 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 229960000623 carbamazepine Drugs 0.000 description 2
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002621 endocannabinoid Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 210000000548 hind-foot Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000001272 neurogenic effect Effects 0.000 description 2
- 210000000929 nociceptor Anatomy 0.000 description 2
- 108091008700 nociceptors Proteins 0.000 description 2
- 229940005483 opioid analgesics Drugs 0.000 description 2
- 210000001428 peripheral nervous system Anatomy 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 210000002972 tibial nerve Anatomy 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 102000018208 Cannabinoid Receptor Human genes 0.000 description 1
- 108050007331 Cannabinoid receptor Proteins 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 206010012218 Delirium Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 208000027534 Emotional disease Diseases 0.000 description 1
- 229940124602 FDA-approved drug Drugs 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000004356 Hysteria Diseases 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 150000001200 N-acyl ethanolamides Chemical class 0.000 description 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 description 1
- 208000036992 Psychogenic pain disease Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000027520 Somatoform disease Diseases 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 208000012839 conversion disease Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 201000005518 mononeuropathy Diseases 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 208000027753 pain disease Diseases 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 238000010149 post-hoc-test Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000001044 sensory neuron Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 210000001032 spinal nerve Anatomy 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008542 thermal sensitivity Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
材料及び方法
試験したカンナビノイドは、CBG、CBC、CBDV及びTHCVであった。加えて、カンナビノイドCBDがこの実施例において使用した神経因性疼痛の動物モデルにおいて正の結果を過去に示しているため、このカンナビノイドを使用した。カンナビノイドは、精製された大麻植物の全植物抽出物から調製した。カンナビノイドは、腹腔内(i.p.)投与のためにリンゲル液/0.5%ジメチルスルホキシド(DMSO)中に溶解した。
i)無処置対照マウス(n=8)、
ii)ビヒクルで治療した擬似手術マウス(n=8)、
iii)カンナビノイドで治療した擬似手術マウス(n=8)、
iv)ビヒクルで治療したSNIマウス(n=8)、
v)カンナビノイドで治療したSNIマウス(n=8)。
機械的アロデニアを、Dynamic Plantar Anesthesiometer(Ugo Basile, Varese, Italy)を使用することによって測定した。マウスを、金属メッシュ表面上に位置する閉鎖空間の2つの区画のうちの1つにおいて自由に運動させた。マウスを、いずれの測定を行う前にも、試験環境に順応させた。その後、機械的刺激を、自動試験装置によって試験チャンバーの床の下からマウスの後足の足底の表面に送達した。鋼ロッド(2mm)を電子的浮力(10秒で0g〜30g)を用いて押した。動物がその後足を引っ込めると、機械的刺激が自動的に取り除かれ、力を0.1gの桁に四捨五入して(to the nearest 0.1 g)記録した。
行動データ及び分子データは、平均値±S.E.Mとして示した。スチューデント・ニューマン・クールの事後検定を後で行うANOVAを使用して、群間の統計的有意性を決定した。P<0.01を統計的に有意とみなした。
機械的引込め閾値
図2、図4、図6、図8及び図10は、試験したカンナビノイド(それぞれ、CBC、CBG、CBDV、THCV、及びCBD(比較用))に関して得られた機械的引込め閾値データを示す。棒グラフは、動物にその後足を引っ込めさせるのに必要とされる重量(単位:グラム)を示す。明らかなように、試験したカンナビノイドの全てが、SNIを有する動物についてその動物がその足を引っ込めるまでに適用される重量を増大させることが可能であり、それによって、種々の度合いで、神経部分傷害後3日目、7日目及び14日目に機械的アロデニアを防ぐことが可能であった。5.0mg/kgの用量のカンナビノイドの投与を受けた動物においてより大きな効果が観察されたため、鎮痛効果は用量依存的であった。
図3、図5、図7、図9及び図11は、試験したカンナビノイド(それぞれ、CBC、CBG、CBDV、THCV、及びCBD(比較用))に関して得られた熱的引込め潜時データを示す。棒グラフは、動物がその足を熱源から引っ込めるまでの時間(単位:秒)を示す。明らかなように、試験したカンナビノイドの全てが、SNIを有する動物についてその動物がその足を引っ込めるまでの時間を増大させることが可能であり、それによって、種々の度合いで、神経部分傷害後3日目、7日目及び14日目に熱的痛覚過敏症を防ぐことが可能であった。
試験したカンナビノイドの有効性の度合いの差異を確認するために、以下の表に、この実施例において生成されたデータを表形式で記載する。
HED=動物用量(mg/kg)×(動物のKm/ヒトのKm)
マウスのKmは3であり、ラットの値は6であり、ヒトのKmは37である。
したがって、およそ60kgのヒトに関しては、マウスにおける2.5mg/kgの用量は、約12mgのヒトの1日量に等しいと考えられる。
Claims (5)
- 純粋、合成、又は単離された状態のカンナビジバリン(CBDV)を含むアロデニアを治療するための医薬組成物(但し、CBDV以外のカンナビノイドを含まない)。
- 前記CBDVが、アロデニアを軽減するための効果的なヒトの1日量である5mg〜100mgで存在する、請求項1に記載の医薬組成物。
- 前記効果的なヒトの1日量が10mg〜50mgである、請求項2に記載の医薬組成物。
- 前記CBDVが長期の治療期間での使用のために包装される、請求項1〜3のいずれか一項に記載の医薬組成物。
- 前記長期の治療期間が少なくとも7日間である、請求項4に記載の医薬組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1108506.5A GB2491118B (en) | 2011-05-20 | 2011-05-20 | Cannabinoids for use in the treatment of neuropathic pain |
GB1108506.5 | 2011-05-20 | ||
PCT/GB2012/051129 WO2012160358A1 (en) | 2011-05-20 | 2012-05-18 | Cannabinoids for use in the treatment of neuropathic pain |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2014513715A JP2014513715A (ja) | 2014-06-05 |
JP6147249B2 true JP6147249B2 (ja) | 2017-06-14 |
Family
ID=44279366
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014510885A Active JP6147249B2 (ja) | 2011-05-20 | 2012-05-18 | 神経因性疼痛の治療において使用するためのカンナビノイド |
Country Status (21)
Country | Link |
---|---|
US (1) | US9895342B2 (ja) |
EP (1) | EP2709604B1 (ja) |
JP (1) | JP6147249B2 (ja) |
KR (1) | KR20140037124A (ja) |
CN (1) | CN103533930A (ja) |
AR (1) | AR086398A1 (ja) |
AU (1) | AU2012260611B2 (ja) |
BR (1) | BR112013029773A2 (ja) |
CA (1) | CA2833099C (ja) |
CO (1) | CO6811867A2 (ja) |
DK (1) | DK2709604T3 (ja) |
EA (1) | EA201391733A1 (ja) |
ES (1) | ES2624308T3 (ja) |
GB (2) | GB2524689B (ja) |
IL (1) | IL229474B (ja) |
MX (1) | MX2013013141A (ja) |
PT (1) | PT2709604T (ja) |
SG (1) | SG194839A1 (ja) |
TW (1) | TW201249425A (ja) |
WO (1) | WO2012160358A1 (ja) |
ZA (1) | ZA201309364B (ja) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2530001B (en) | 2014-06-17 | 2019-01-16 | Gw Pharma Ltd | Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy |
GB2531282A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
US10499584B2 (en) | 2016-05-27 | 2019-12-10 | New West Genetics | Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles |
JP2019524655A (ja) | 2016-06-29 | 2019-09-05 | キャンサイエンス イノベーションズ インコーポレーテッドCannscience Innovations Inc. | 脱炭酸大麻樹脂、その使用、及びそれを製造する方法 |
US10239808B1 (en) | 2016-12-07 | 2019-03-26 | Canopy Holdings, LLC | Cannabis extracts |
WO2018236957A1 (en) * | 2017-06-20 | 2018-12-27 | Nexien Biopharma, Inc. | METHOD AND COMPOSITIONS FOR TREATING REST-FREE LEG SYNDROME |
CN109498606A (zh) | 2017-09-15 | 2019-03-22 | 汉义生物科技(北京)有限公司 | 一种含有大麻二酚和/或次大麻二酚的组合物及其在治疗痛经中的应用 |
US20200289458A1 (en) * | 2017-09-22 | 2020-09-17 | Inmed Pharmaceuticals Inc. | Topical formulations of cannabinoids and use thereof in the treatment of pain |
WO2019147690A1 (en) * | 2018-01-23 | 2019-08-01 | High Sierra Technologies, Inc. | Cannabis products modified by removing volatile organic compounds and adding volatile unsaturated hydrocarbons |
WO2019152736A1 (en) | 2018-01-31 | 2019-08-08 | Canopy Holdings, LLC | Hemp powder |
GB201806953D0 (en) | 2018-04-27 | 2018-06-13 | Gw Res Ltd | Cannabidiol Preparations |
CA3119729A1 (en) | 2018-10-10 | 2020-04-16 | Treehouse Biotech, Inc. | Synthesis of cannabigerol |
CA3102473C (en) * | 2019-05-03 | 2021-07-06 | Zyus Life Sciences Inc. | Formulation for pain management |
JP2023523275A (ja) * | 2020-04-24 | 2023-06-02 | ジュス・ライフ・サイエンシーズ・インコーポレイテッド | 疼痛管理のためのカンナビクロメン製剤 |
US11672761B2 (en) | 2020-11-16 | 2023-06-13 | Orcosa Inc. | Rapidly infusing platform and compositions for therapeutic treatment in humans |
CN116648241A (zh) * | 2021-04-14 | 2023-08-25 | 成都百裕制药股份有限公司 | 氘代苯酚衍生物及其制备方法和用途 |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL126203A (en) | 1996-03-25 | 2002-12-01 | Lilly Co Eli | A synergistic painkiller that contains olenzapine and another painkiller |
US6949582B1 (en) | 1999-05-27 | 2005-09-27 | Wallace Walter H | Method of relieving analgesia and reducing inflamation using a cannabinoid delivery topical liniment |
GB2377633A (en) * | 2001-05-11 | 2003-01-22 | Gw Pharmaceuticals Ltd | Pharmaceutical compositions comprising the cannabinoids THC and CBD |
GB2381194A (en) * | 2001-09-07 | 2003-04-30 | Gw Pharmaceuticals Ltd | Pharmaceutical formulations |
US7025992B2 (en) | 2001-02-14 | 2006-04-11 | Gw Pharma Limited | Pharmaceutical formulations |
US6730330B2 (en) | 2001-02-14 | 2004-05-04 | Gw Pharma Limited | Pharmaceutical formulations |
SI1361864T1 (sl) * | 2001-02-14 | 2014-04-30 | Gw Pharma Limited | Kapljevite pršilne formulacije za bukalno administracijo kanabinoidov |
US10004684B2 (en) * | 2001-02-14 | 2018-06-26 | Gw Pharma Limited | Pharmaceutical formulations |
CH695661A5 (de) | 2001-03-06 | 2006-07-31 | Forsch Hiscia Ver Fuer Krebsfo | Pharmazeutische Zusammensetzung. |
EP1243262B1 (en) | 2001-03-20 | 2006-05-31 | Schwarz Pharma Ag | Novel use of a peptide class of compound for treating non-neuropathic inflammatory pain |
GB2381450B (en) | 2001-10-31 | 2006-05-31 | Gw Pharma Ltd | Compositions for administration of natural or synthetic cannabinoids by vaporisation |
ATE533472T1 (de) | 2002-08-14 | 2011-12-15 | Gw Pharma Ltd | Flüssige cannabinoid-formulierungen zur verabreichung an die schleimhäute |
GB2392093B (en) * | 2002-08-14 | 2006-03-08 | Gw Pharma Ltd | Pharmaceutical formulations |
US6946150B2 (en) | 2002-08-14 | 2005-09-20 | Gw Pharma Limited | Pharmaceutical formulation |
GB2391865B (en) | 2002-08-14 | 2005-06-01 | Gw Pharma Ltd | Improvements in the extraction of pharmaceutically active components from plant materials |
GB0222077D0 (en) * | 2002-09-23 | 2002-10-30 | Gw Pharma Ltd | Methods of preparing cannabinoids from plant material |
GB2394894B (en) | 2002-11-04 | 2005-08-31 | G W Pharma Ltd | New use for pharmaceutical composition |
GB2414933B (en) | 2004-06-08 | 2009-07-15 | Gw Pharma Ltd | Cannabinoid compositions for the treatment of disease and/or symptoms in arthritis |
US7968594B2 (en) | 2005-04-27 | 2011-06-28 | Gw Pharma Limited | Pharmaceutical compositions for the treatment of pain |
EP1747786A3 (en) | 2005-07-25 | 2007-04-25 | Perdix Eurogroup S.L. | Natural product in cream with anti-vitiligo therapeutic properties |
US20070036873A1 (en) | 2005-07-27 | 2007-02-15 | Shibnath Ghosal | Method of treatment or management of stress |
CA2517313A1 (en) * | 2005-08-26 | 2007-02-26 | Queen's University At Kingston | Methods and therapies for potentiating therapeutic activities of a cannabinoid receptor agonist via administration of a cannabinoid receptor antagonist |
GB2432312A (en) | 2005-11-01 | 2007-05-23 | Gw Pharma Ltd | Pharmaceutical compositions for the treatment of pain |
GB2439393B (en) * | 2006-06-23 | 2011-05-11 | Gw Pharma Ltd | Cannabinoids for use in the treatment of neuropathic pain |
GB2448535A (en) * | 2007-04-19 | 2008-10-22 | Gw Pharma Ltd | New use for cannabinoid-containing plant extracts |
GB2450493A (en) * | 2007-06-25 | 2008-12-31 | Gw Pharma Ltd | Cannabigerol for use in treatment of diseases benefiting from agonism of CB1 and CB2 cannabinoid receptors |
-
2011
- 2011-05-20 GB GB1512357.3A patent/GB2524689B/en active Active
- 2011-05-20 GB GB1108506.5A patent/GB2491118B/en active Active
-
2012
- 2012-05-09 TW TW101116491A patent/TW201249425A/zh unknown
- 2012-05-14 AR ARP120101707A patent/AR086398A1/es unknown
- 2012-05-18 WO PCT/GB2012/051129 patent/WO2012160358A1/en active Application Filing
- 2012-05-18 MX MX2013013141A patent/MX2013013141A/es not_active Application Discontinuation
- 2012-05-18 CA CA2833099A patent/CA2833099C/en active Active
- 2012-05-18 EA EA201391733A patent/EA201391733A1/ru unknown
- 2012-05-18 SG SG2013082649A patent/SG194839A1/en unknown
- 2012-05-18 CN CN201280024106.4A patent/CN103533930A/zh active Pending
- 2012-05-18 PT PT127224954T patent/PT2709604T/pt unknown
- 2012-05-18 KR KR1020137033069A patent/KR20140037124A/ko not_active Application Discontinuation
- 2012-05-18 BR BR112013029773A patent/BR112013029773A2/pt active Search and Examination
- 2012-05-18 AU AU2012260611A patent/AU2012260611B2/en active Active
- 2012-05-18 EP EP12722495.4A patent/EP2709604B1/en active Active
- 2012-05-18 JP JP2014510885A patent/JP6147249B2/ja active Active
- 2012-05-18 DK DK12722495.4T patent/DK2709604T3/en active
- 2012-05-18 ES ES12722495.4T patent/ES2624308T3/es active Active
- 2012-05-18 US US14/118,563 patent/US9895342B2/en active Active
-
2013
- 2013-11-17 IL IL229474A patent/IL229474B/en active IP Right Grant
- 2013-12-02 CO CO13282297A patent/CO6811867A2/es not_active Application Discontinuation
- 2013-12-11 ZA ZA2013/09364A patent/ZA201309364B/en unknown
Also Published As
Publication number | Publication date |
---|---|
GB2524689B (en) | 2016-01-27 |
CA2833099C (en) | 2020-11-03 |
SG194839A1 (en) | 2013-12-30 |
GB2491118B (en) | 2015-12-30 |
CA2833099A1 (en) | 2012-11-29 |
DK2709604T3 (en) | 2017-05-15 |
MX2013013141A (es) | 2014-02-17 |
KR20140037124A (ko) | 2014-03-26 |
GB201512357D0 (en) | 2015-08-19 |
US9895342B2 (en) | 2018-02-20 |
CN103533930A (zh) | 2014-01-22 |
EP2709604B1 (en) | 2017-02-01 |
IL229474A0 (en) | 2014-01-30 |
BR112013029773A2 (pt) | 2017-01-17 |
US20140107192A1 (en) | 2014-04-17 |
IL229474B (en) | 2018-11-29 |
AU2012260611A1 (en) | 2013-12-12 |
AU2012260611B2 (en) | 2017-06-15 |
GB2491118A (en) | 2012-11-28 |
PT2709604T (pt) | 2017-05-17 |
EP2709604A1 (en) | 2014-03-26 |
US20140378539A9 (en) | 2014-12-25 |
EA201391733A1 (ru) | 2014-04-30 |
ES2624308T3 (es) | 2017-07-13 |
AR086398A1 (es) | 2013-12-11 |
ZA201309364B (en) | 2015-04-29 |
WO2012160358A1 (en) | 2012-11-29 |
GB201108506D0 (en) | 2011-07-06 |
CO6811867A2 (es) | 2013-12-16 |
JP2014513715A (ja) | 2014-06-05 |
TW201249425A (en) | 2012-12-16 |
NZ618246A (en) | 2016-01-29 |
GB2524689A (en) | 2015-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6147249B2 (ja) | 神経因性疼痛の治療において使用するためのカンナビノイド | |
US20190224140A1 (en) | Cannabinoids for use in the treatment of neuropathic pain | |
CA2626074A1 (en) | A combination of cannabinoids for the treatment of peripheral neurophatic pain | |
JP2010531298A (ja) | 疼痛を治療するための局所用組成物 | |
JP2016508155A (ja) | 固溶体組成物および激痛における使用 | |
Cheng et al. | Efficacy of different irrigation solutions on the early debridement of open fracture in rats | |
MX2007003948A (es) | Composicion farmaceutica en forma de tableta sublingual que comprende un antiinflamatorio no esteroideo y un analgesico opiaceo para el manejo del dolor. | |
RU2701720C1 (ru) | Комбинации пальмитоилэтаноламида для лечения хронической боли | |
JP2009084209A (ja) | Trpv4受容体抑制剤 | |
Al-Harrasi et al. | Olfactory Aromatherapy vs COVID-19: A Systematic Review | |
US11395813B1 (en) | Cannabinoids based pharmaceutical composition | |
NZ618246B2 (en) | Cannabinoids for use in the treatment of neuropathic pain | |
US20230255899A1 (en) | Cannabinoid Monoterpene Based Pharmaceutical Topical Composition For MusculoSkeletal Pain | |
Haesler | Evidence summary: lymphatic filariasis: prevention | |
Habib et al. | Antinociceptive and Anti-inflammatory Effects of Combined Administration of a-tocopherol and Morphine in Long Evans Rats | |
EP2744497A2 (en) | Therapeutic combinations of netupitant and palonosetron | |
Hargreaves | Neuroendocrine modulation of pain |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150501 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160315 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20160318 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160613 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20160624 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20160624 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160805 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160913 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20161101 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170228 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20170414 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170509 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170516 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6147249 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |